Why Did United Therapeutics Plunge 12.89%?
Tuesday, Jun 10, 2025 7:32 am ET
1min read On June 10, 2025, United Therapeutics experienced a significant drop of 12.89% in pre-market trading, sparking concerns among investors about the company's future prospects.
JPMorgan Chase & Co. recently adjusted their outlook on United Therapeutics, lowering their price target from $355.00 to $350.00 while maintaining an "overweight" rating. This revision reflects the bank's updated analysis of the company's financial performance and market position.
Two Sigma Investments LP has also made notable moves, acquiring 52 shares of United Therapeutics. This investment signals confidence in the company's long-term growth potential, despite recent market volatility.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
_442a2dcc1749832873286.jpeg)
_e68fac6d1749831664430.jpeg)
